WHO预认证部门第11次邀请生殖健康产品生产商提交产品评估意向书（EOI）
11th Invitation to Manufacturers of Reproductive Health Products to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit
WHO预认证部门第11次邀请生殖健康产品生产商提交产品评估意向书（EOI），此次更新系应WHO生命周期健康与生殖部门请求作出。清单涵盖妊娠期高血压疾病管理用药（甲基多巴250 mg片剂、硝苯地平10、20 mg片剂、拉贝洛尔100 mg片剂及10 mg注射剂、肼屈嗪5 mg注射剂）和妊娠期重度缺铁性贫血用药（羧基麦芽糖铁50mg/ml铁、蔗糖铁20mg/ml铁，均为10 ml瓶）。
News
29 October, 2026 - 00:12 (CET)
Alerts
The Invitation Manufacturers of Reproductive Health Products to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit was recently updated following a request by the WHO Lifecourse Health and Reproduction Department.
- Under Management of hypertensive disorders of pregnancy:
- Alpha Methyl dopa 250 mg tablet
- Nifedipine 10, 20 mg tablet
- Labetalol 100 mg tablet
- Labetalol 10 mg Injection (5mg/ml in 2ml ampoule)
- Hydralazine 5 mg Injection (5 mg/ml in 2ml ampoule)
- Under Management of severe iron deficiency anemia during pregnancy:
- Ferric carboxymaltose50mg/ml iron, 10 ml vial
- Iron sucrose 20mg/ml iron, 10ml vial
The UN maternal mortality estimates, about 260000 women died due to maternal causes in 2023. Hypertensive disorders of pregnancy remained a leading cause of mortality worldwide. Similarly, anemia affects approximately 37% of pregnant women globally (WHO Global Anemia Estimates, 2021 Edition). Women in low-resource countries are at a higher risk of developing both anemia and pre-eclampsia compared to those in high-resource countries. Thus, improving the availability and quality of medicines for prevention and treatment of PE/E and anemia is necessary to help reduce the risk of adverse outcomes to a mother and to a baby as well as maximize health equities.
Links
来源：WHO 药品预认证与检查动态 · extranet.who.int